Piroxicam 20 mg – [20 capsules]

Pyroxicam is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic effects. Non-selectively inhibits the activity of cyclooxygenase 1 and cyclooxygenase 2 (COX1 and COX2), inhibits the synthesis of prostaglandins in the inflammation focus and the central nervous system, inhibits the exudative and proliferative phase of inflammation. Inhibits neutrophil aggregation and formation of superoxide anions in neutrophils, migration of polymorphonuclear cells and monocytes to the inflammation focus. Reduces the release of lysosomal enzymes from stimulated leukocytes. Reduces pyrogenic effect of prostaglandins on the thermoregulation center. Reduces the severity of pain syndrome of moderate intensity, increasing the threshold of pain sensitivity to biological amines. Analgesic effect appears 30 min after oral administration. After a single dose, the effect lasts for 24 hours. In joint syndrome, it relieves or reduces inflammation and pain at rest when moving, reduces morning stiffness and joint swelling, helps to increase range of motion. In algodysmenorrhea (being an inhibitor of prostaglandin synthesis in the endometrium) it relieves pain syndrome.

Diseases of the musculoskeletal system: rheumatoid arthritis, osteoarthritis, spondylitis, sciatica, psoriatic arthropathy, gout, tendovaginitis, bursitis,

Bechterew’s disease (ankylosing spondyloarthritis), spinal pain, neuralgia, myalgia, postoperative and posttraumatic pain, extra-articular rheumatic diseases, inflammation of soft tissues. Algodysmenorrhea. Designed for symptomatic therapy, reduction of pain and inflammation at the time of use, does not affect the progression of the disease.

– Hypersensitivity to pyroxicam, other non-steroidal anti-inflammatory drugs, components of the drug;

– Complete or incomplete combination of bronchial asthma, recurrent polyposis of nasal mucosa or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including history);

– erosive-ulcerative changes of the mucous membrane of the stomach or duodenum, active gastrointestinal bleeding; cerebrovascular or other bleeding;

– Inflammatory bowel disease (Crohn’s disease, non-specific ulcerative colitis) in the acute phase;

– Hemophilia and other blood clotting disorders;

– decompensated heart failure;

– hepatic insufficiency or any active liver disease;

– severe renal insufficiency (creatinine clearance less than 30 ml/min), progressive renal disease, confirmed hyperkalemia;

– the period after coronary artery bypass grafting;

– Pregnancy, breast-feeding;

– Children under 15 years of age.